Georgia Chenevix-Trench

Australian scientist

DBpedia resource is: http://dbpedia.org/resource/Georgia_Chenevix-Trench

Abstract is: Georgia Chenevix-Trench FAA, FAHMS (born 8 February 1959) is an Australian cancer researcher who investigates genetic predispositions to cancer. Chenevix-Trench was born in Nairobi, Kenya. She received her undergraduate degree (BSc(Hons)) in 1980 from the Department of Genetics at Trinity College in Ireland and was subsequently awarded her PhD in 1985 from the Department of Human Genetics at the Medical College of Virginia, USA. and in 1986 she commenced her post-doctoral work there. In 1989 she moved to Australia where she started working as a research officer at the Queensland Institute of Medical Research (QIMR). She currently works at the QIMR Berghofer Medical Research Institute, where she heads a cancer genetics research lab. Chenevix-Trench has published over 400 papers in peer reviewed journals and has been actively involved in science education and communication. She was elected to the Australian Academy of Science in 2014, for her work on the genetics of breast, ovarian and other cancers, including showing that mutations in the ATM gene confer moderate risks for breast cancer. In 2015 she was elected Fellow of the Australian Academy of Health and Medical Sciences. She was awarded the Suzanne Cory Medal and Lecture by the Australian Academy of Science in 2022.

Born 1959-02-08 in Nairobi (Q3870)

Georgia Chenevix-Trench is …
instance of (P31):
humanQ5

External links are
P6178Dimensions author ID01012310162.58
P646Freebase ID/m/011q64xw
P496ORCID iD0000-0002-1878-2587
P4638The Peerage person IDp3558.htm#i35574

P166award receivedSuzanne Cory MedalQ112136264
Fellow of the Australian Academy of ScienceQ59260322
Fellow of the Australian Academy of Health and Medical SciencesQ59771619
P40childHilary Chenevix MartinQ75486215
Felicity Chenevix MartinQ75486216
P27country of citizenshipAustraliaQ408
P69educated atTrinity College DublinQ258464
Virginia Commonwealth University School of MedicineQ7906670
P108employerQIMR Berghofer Medical Research InstituteQ7270958
P22fatherCharles Pocklington Chenevix TrenchQ52161468
P735given nameGeorgiaQ378694
GeorgiaQ378694
P463member ofAustralian Academy of ScienceQ514105
P25motherMary Elizabeth KirkbrideQ75281691
P106occupationgeneticistQ3126128
P21sex or genderfemaleQ6581072
P26spouseNicholas Gordon MartinQ75281807

Reverse relations

mother (P25)
Q75486216Felicity Chenevix Martin
Q75486215Hilary Chenevix Martin

child (P40)
Q52161468Charles Pocklington Chenevix Trench
Q75281691Mary Elizabeth Kirkbride

author (P50)
Q91209246"I am not a statistic" ovarian cancer survivors' views of factors that influenced their long-term survival
Q3601638611q13 is a susceptibility locus for hormone receptor positive breast cancer
Q3587156719p13.1 is a triple-negative-specific breast cancer susceptibility locus
Q338488952q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy
Q360214067q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium
Q371698739q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium
Q51569689A BRCA1 promoter variant (rs11655505) and breast cancer risk.
Q35656649A Common Cancer Risk-Associated Allele in the hTERT Locus Encodes a Dominant Negative Inhibitor of Telomerase
Q59349476A Comprehensive Gene-Environment Interaction Analysis in Ovarian Cancer using Genome-wide Significant Common Variants
Q92224274A Mendelian randomization analysis of circulating lipid traits and breast cancer risk
Q57265744A Systematic Approach to Analysing Gene-Gene Interactions: Polymorphisms at the Microsomal Epoxide Hydrolase EPHX and Glutathione S-transferase GSTM1, GSTT1, and GSTP1 Loci and Breast Cancer Risk
Q59355837A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk
Q57250674A common coding variant in CASP8 is associated with breast cancer risk
Q33698648A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy
Q37272982A genome wide linkage search for breast cancer susceptibility genes
Q37332232A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk
Q33747778A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2.
Q29417084A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.
Q36013881A genome-wide association study of caffeine-related sleep disturbance: confirmation of a role for a common variant in the adenosine receptor
Q35195145A large, dominant pedigree of atrioventricular septal defect (AVSD): exclusion from the Down syndrome critical region on chromosome 21.
Q37619303A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium
Q35089479A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population
Q92711687A network analysis to identify mediators of germline-driven differences in breast cancer prognosis
Q36152991A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers
Q40155430A novel corepressor, BCoR-L1, represses transcription through an interaction with CtBP.
Q57265807A protein-truncating mutation inCYP17A1 in three sisters with early-onset breast cancer
Q34369388A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia
Q85312916A role for common genomic variants in the assessment of familial breast cancer
Q119213000A short ERK5 isoform modulates nucleocytoplasmic shuttling of active ERK5 and associates with poor survival in breast cancer
Q74459364A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers
Q57305942A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer
Q33947899ABCA transporter gene expression and poor outcome in epithelial ovarian cancer
Q45903986ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.
Q37227494ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas
Q35959358ATM and genome maintenance: defining its role in breast cancer susceptibility
Q37417780AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study
Q64458508Abstract 5493: Genome-wide study of carboplatin and paclitaxel disposition in ovarian cancer patients
Q63681770Abstract P6-10-06: Rational combination therapy against triple-negative breast cancer
Q38406780Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study
Q52647897Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study.
Q39437211Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers
Q71733519Allelic loss on chromosome 7q in ovarian adenocarcinomas: two critical regions and a rearrangement of the PLANH1 locus
Q45067214Allelic variation of the c-raf-1 oncogene in non-Hodgkin's lymphoma
Q41276116Allelic variation of the c-raf-1 proto-oncogene in human lymphoma and leukemia.
Q51196598Altered regulation of c-myc in an HL-60 differentiation resistant subclone, HL-60-1E3.
Q53465106An Alu VpA marker on chromosome I demonstrates that replication errors manifest at the adenoma-carcinoma transition in sporadic colorectal tumors.
Q34623703An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)
Q35618307An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers
Q42371458Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci
Q46464326Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients
Q85077261Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients
Q34480599Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource
Q44284336Analysis of gene amplification in head-and-neck squamous-cell carcinoma
Q73259331Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations
Q36831854Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome
Q36623673Analysis of the TGF beta functional pathway in epithelial ovarian carcinoma
Q24656704Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer
Q28185257Analysis of the transcription regulator, CNOT7, as a candidate chromosome 8 tumor suppressor gene in colorectal cancer
Q57269082Androgen receptor exon 1 cag repeat length and risk of ovarian cancer
Q35681656Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis
Q73433559Apparent protection from instability of repeat sequences in cancer-related genes in replication error positive gastrointestinal cancers
Q63681771Application of molecular findings to the diagnosis and management of breast disease: recent advances and challenges
Q42763529Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?
Q35242849Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers
Q34613673Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study
Q30276986Assessing the genetic architecture of epithelial ovarian cancer histological subtypes
Q35156876Assessment of hepatocyte growth factor in ovarian cancer mortality
Q47397042Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study.
Q35218520Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy
Q37684409Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer
Q28138778Assignment of the human slit homologue SLIT2 to human chromosome band 4p15.2
Q45979098Association analysis identifies 65 new breast cancer risk loci.
Q27851709Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer
Q84635142Association between KRAS rs61764370 and triple-negative breast cancer--a false positive?
Q33828680Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival
Q37200998Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study
Q37151872Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set.
Q37292963Association of ESR1 gene tagging SNPs with breast cancer risk
Q91271723Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness
Q36072765Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study
Q46707380Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis
Q36178189Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.
Q37684672Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21.
Q37268494Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry
Q114182713Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment
Q99609984Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer
Q72671791Association of the SS genotype of the L-myc gene and loss of 18q sequences with a worse clinical prognosis in colorectal cancers
Q34801008Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers
Q35957703Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer
Q39423088Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study
Q35022847Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies
Q35523236Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers
Q35532898Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium
Q57056093Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis
Q57391849Atopy in Australia
Q36393308BCoR-L1 variation and breast cancer
Q57306053BRAF polymorphisms and the risk of ovarian cancer of low malignant potential
Q64039257BRCA1 and BRCA2 Pathogenic Sequence Variants in Women of African Origin or Ancestry
Q33337136BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression
Q37002955BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers
Q57306056BRCA2 arg372hispolymorphism and epithelial ovarian cancer risk
Q35896230BamHI RFLP of the inhibin beta B (INHBB) chain gene on chromosome 2.
Q42493776Basal cell carcinoma in chronic arsenicism occurring in Queensland, Australia, after ingestion of an asthma medication
Q42462369Basal cell carcinomas, coarse sparse hair, and milia
Q68197898Basal cell naevus syndrome
Q40527413BcII RFLP of the plasminogen activator inhibitor type 2 gene (PLANH) on chromosome 18q21-q23.
Q46115524Body mass index and breast cancer survival: a Mendelian randomization analysis
Q100457582Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk
Q114182645Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores
Q34327945Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2
Q37410693Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab
Q35940158Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.
Q37839530Breast cancer stem cells: treatment resistance and therapeutic opportunities
Q47684602CDX2, a human homologue of Drosophila caudal, is mutated in both alleles in a replication error positive colorectal cancer
Q36998293COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration
Q24810733CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study
Q73088381CYP17 promoter polymorphism and breast cancer in Australian women under age forty years
Q73666685CYP17 promotor polymorphism and ovarian cancer risk
Q92005489Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families
Q114657791Cancer Risks Associated With and Pathogenic Variants
Q92636519Candidate Causal Variants at the 8p12 Breast Cancer Risk Locus Regulate DUSP4
Q34963894Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers
Q35693892Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci
Q41456461Cep55 regulates embryonic growth and development by promoting Akt stability in zebrafish
Q52691103Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient.
Q96962174Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
Q38309212Characterization of the breast cancer associated ATM 7271T>G (V2424G) mutation by gene expression profiling
Q92475989Chromatin interactome mapping at 139 independent breast cancer risk signals
Q78845343Chromosome 8 genetic analysis and phenotypic characterization of 21 ovarian cancer cell lines
Q45077098Chromosome analysis of 30 cases of non-Hodgkin's lymphoma
Q35782435Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer
Q35447780Classification of BRCA1 missense variants of unknown clinical significance
Q35196271Cleft lip with or without cleft palate: associations with transforming growth factor alpha and retinoic acid receptor loci
Q57306048Clinical Classification ofBRCA1andBRCA2DNA Sequence Variants: The Value of Cytokeratin Profiles and Evolutionary Analysis—A Report From the kConFab Investigators
Q36080881Colorectal carcinomas show frequent allelic loss on the long arm of chromosome 17 with evidence for a specific target region
Q37657957Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer
Q94486442Combined associations of a polygenic risk score and classical risk factors with breast cancer risk
Q35668946Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk
Q57265809Common Polymorphisms in ERCC2 (Xeroderma pigmentosum D) are not Associated with Breast Cancer Risk
Q36839777Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers
Q34126314Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer
Q34394665Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction
Q35889575Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.
Q24655824Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
Q81621687Common chromosomal fragile site FRA16D mutation in cancer cells
Q37732823Common genetic variants and cancer risk in Mendelian cancer syndromes
Q33742096Common genetic variants and modification of penetrance of BRCA2-associated breast cancer
Q34949394Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers
Q47139520Common genomic variants associated with breast cancer predict the risk of second primary breast cancer diagnosis.
Q35794653Common germline polymorphisms associated with breast cancer-specific survival
Q34379032Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium
Q33947829Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers
Q36393232Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers
Q29417145Common variants at 19p13 are associated with susceptibility to ovarian cancer
Q35870067Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers
Q36255665Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer
Q37434133Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers
Q34213403Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers
Q31082788Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)
Q33851325Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis
Q34181322Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer
Q37155532Consortium analysis of 7 candidate SNPs for ovarian cancer
Q96123636Copy Number Variation and Ovarian Cancer Risk-Letter
Q45950681Correction: BCoR-L1 variation and breast cancer.
Q57266620Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer
Q45793899Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer.
Q57278898Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)
Q91090014Correction: Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers
Q53298473Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust.
Q70182016Cytogenetic and molecular genetic studies of a patient with atypical lymphoid hyperplasia
Q42482417DHPLC analysis of patients with Nevoid Basal Cell Carcinoma Syndrome reveals novel PTCH missense mutations in the sterol-sensing domain
Q21144874DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers
Q33708624DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status
Q63372140DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status
Q37685729DNA mismatch repair gene MSH6 implicated in determining age at natural menopause
Q41672068De novo mutations of the Patched gene in nevoid basal cell carcinoma syndrome help to define the clinical phenotype
Q36622573Decreased expression of the Id3 gene at 1p36.1 in ovarian adenocarcinomas
Q40760869Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS).
Q96590073Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE)
Q40707128Distinct phenotype in maternal uniparental disomy of chromosome 14.
Q22066027Dominant Negative ATM Mutations in Breast Cancer Families
Q43924266Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
Q57265812Double-Strand Break Repair Gene Polymorphisms and Risk of Breast or Ovarian Cancer
Q33824208ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study
Q36245609Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers
Q67975809Elevation of follicular phase inhibin and luteinizing hormone levels in mothers of dizygotic twins suggests nonovarian control of human multiple ovulation
Q24633316Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer
Q112637570Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer
Q57250672Erratum: Corrigendum: A common coding variant in CASP8 is associated with breast cancer risk
Q57319395Erratum: Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer
Q57306046Erratum: Validating genetic risk associations for ovarian cancer through the International Ovarian Cancer Association Consortium
Q34767345Estimating single nucleotide polymorphism associations using pedigree data: applications to breast cancer
Q33932856Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium
Q36966218Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study
Q34659939Evaluating the repair of DNA derived from formalin-fixed paraffin-embedded tissues prior to genomic profiling by SNP-CGH analysis
Q99720321Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses
Q33614244Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers
Q37481884Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA).
Q21144976Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot"
Q36352389Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers
Q37745041Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers
Q34806825Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2.
Q35653910Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk
Q34613604Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers
Q34687073Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study
Q35643949Evidence for an association between nonsyndromic cleft lip with or without cleft palate and a gene located on the long arm of chromosome 4.
Q57287527Evidence for microsatellite instability in bilateral breast carcinomas
Q37347027Evidence of a genetic link between endometriosis and ovarian cancer
Q35064451Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation
Q37342144Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation
Q25257572Evolutionary conservation analysis increases the colocalization of predicted exonic splicing enhancers in the BRCA1 gene with missense sequence changes and in-frame deletions, but not polymorphisms
Q54648951Exclusion of APC and MCC as the gene defect in one family with familial juvenile polyposis.
Q38845261Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk
Q33863235Exploring the link between MORF4L1 and risk of breast cancer
Q42490438Expression of beta-catenin, a key mediator of the WNT signaling pathway, in basal cell carcinoma
Q42483687Expression of p53 in arsenic-related and sporadic basal cell carcinoma
Q37594336FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium
Q73443345Fertility and incidence of KRAS2 mutations in borderline ovarian adenocarcinomas
Q42484642Fine deletion mapping on the long arm of chromosome 9 in sporadic and familial basal cell carcinomas
Q28243330Fine genetic mapping of the gene for nevoid basal cell carcinoma syndrome
Q37236216Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs).
Q36111237Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus
Q36087170Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Q35524465Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2.
Q61230414Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes
Q92480972Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
Q39844032Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer
Q36248936Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk
Q34903062Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1.
Q37367871Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1.
Q34979715Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium
Q44116963Folate and related micronutrients, folate-metabolising genes and risk of ovarian cancer
Q48030071Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
Q70571548Frequent loss of heterozygosity on chromosome 14 occurs in advanced colorectal carcinomas
Q58025019Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus
Q51843102Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors.
Q91016919Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus.
Q114182808Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element
Q42366538Functional dissection of breast cancer risk-associated TERT promoter variants
Q71767608Functional evidence for a colorectal cancer tumor suppressor gene at chromosome 8p22-23 by monochromosome transfer
Q36124728Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus
Q58047816Functional polymorphisms in the TERT promoter are associated with risk of serious ovarian and breast cancer
Q34031757Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers
Q36742577Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers
Q43146116Further evidence for an association between genetic variation in transforming growth factor alpha and cleft lip and palate
Q35195046Further localization of the gene for nevoid basal cell carcinoma syndrome (NBCCS) in 15 Australasian families: linkage and loss of heterozygosity.
Q36956156GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer
Q34205748Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome
Q52828093Gene expression in melanoma cell lines and cultured melanocytes: correlation between levels of c-src-1, c-myc and p53.
Q33622653Gene expression profiling of formalin-fixed, paraffin-embedded familial breast tumours using the whole genome-DASL assay
Q63372138Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression
Q36175072Gene-panel sequencing and the prediction of breast-cancer risk
Q62583319Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk
Q57306006Genetic and Histopathologic Evaluation ofBRCA1andBRCA2DNA Sequence Variants of Unknown Clinical Significance
Q35999323Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study
Q108609948Genetic insights into biological mechanisms governing human ovarian ageing
Q29417068Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study
Q35925620Genetic predisposition to ductal carcinoma in situ of the breast
Q35151684Genetic predisposition to in situ and invasive lobular carcinoma of the breast
Q35022825Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers
Q35179897Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study
Q34453723Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium
Q34955369Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk
Q34378972Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade
Q43167965Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants
Q30000080Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent
Q92387949Genetically Predicted Levels of DNA Methylation Biomarkers and Breast Cancer Risk: Data From 228 951 Women of European Descent
Q95304100Genome-Wide Association Meta-Analysis of Single-Nucleotide Polymorphisms and Symptomatic Venous Thromboembolism during Therapy for Acute Lymphoblastic Leukemia and Lymphoma in Caucasian Children
Q28388497Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types
Q36218993Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium
Q36842233Genome-wide association analysis identifies three new breast cancer susceptibility loci
Q36352038Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM
Q35996692Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer
Q63681757Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer
Q24622610Genome-wide association studies identify four ER negative-specific breast cancer risk loci
Q92534414Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women
Q37202841Genome-wide association study for ovarian cancer susceptibility using pooled DNA.
Q95329367Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses
Q24645441Genome-wide association study identifies novel breast cancer susceptibility loci
Q27008356Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk
Q64040390Genome-wide association study of germline variants and breast cancer-specific mortality
Q48171906Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer
Q33778612Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA.
Q59566871Genomic analyses for age at menarche identify 389 independent signals and indicate BMI-independent effects of puberty timing on cancer susceptibility
Q72649470Genomic instability occurs in colorectal carcinomas but not in adenomas
Q44734673Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Q33901605Germ-line variation at a functional p53 binding site increases susceptibility to breast cancer development
Q64083344Germline deletion of in familial acute lymphoblastic leukemia
Q35114576Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer
Q36916243Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer
Q114182677Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis
Q42481341Glutathione S-transferase GSTM1 null genotype is not overrepresented in Australian patients with nevoid basal cell carcinoma syndrome or sporadic melanoma
Q71888275Glutathione S-transferase M1 and T1 polymorphisms: susceptibility to colon cancer and age of onset
Q35106767Growing recognition of the role for rare missense substitutions in breast cancer susceptibility
Q55333927Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten.
Q34173413HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer
Q35382206Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers
Q57471595Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study
Q36276540Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization
Q35551911Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.
Q33330850Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics
Q36566003High content screening application for cell-type specific behaviour in heterogeneous primary breast epithelial subpopulations
Q119213179High-throughput allelic expression imbalance analyses identify candidate breast cancer risk genes
Q35889267Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors
Q33551425Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study
Q35102646Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk
Q37006170Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.
Q36465306Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?
Q36720814Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk
Q112717190Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer
Q59291228Identification of a genetic variant associated with treatment outcome in ovarian cancer: the potential role of cholesterol metabolism as a determinant of response to chemotherapy
Q36859142Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer
Q36086247Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus
Q47161199Identification of new breast cancer predisposition genes via whole exome sequencing
Q34038964Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions
Q36014067Identification of novel genetic markers of breast cancer survival
Q35541663Identification of six new susceptibility loci for invasive epithelial ovarian cancer
Q46103372Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer
Q97074448Immune Cell Associations with Cancer Risk
Q33227516Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses
Q71920478Increased expression of the NME1 gene is associated with metastasis in epithelial ovarian cancer
Q37410472Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women
Q37684424Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration
Q35104068Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer
Q38385463Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance
Q30275132Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci
Q34081324Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer
Q30277784Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer
Q34898735Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors
Q60182876Is Schizophrenia a Risk Factor for Breast Cancer?—Evidence From Genetic Data
Q34490781Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32.
Q33917578Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer
Q57191573Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair
Q37725393Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome
Q28267893Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair
Q29416989Large-scale genotyping identifies 41 new loci associated with breast cancer risk
Q91534941LobSig is a multigene predictor of outcome in invasive lobular carcinoma
Q28260002Localization of the gene for human proliferating nuclear antigen/cyclin by in situ hybridization
Q73870254Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas
Q36079621Loss of heterozygosity on the long arm of chromosome 11 in colorectal tumours
Q36616262Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals
Q35119701Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium
Q34354426Lung cancer: intragenic ERBB2 kinase mutations in tumours
Q43145479Lymphoblastoid cell lines from frozen whole blood: a quick and economical safeguard for linkage analysis
Q31043651Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.
Q40556912Mapping of a candidate colorectal cancer tumor-suppressor gene to a 900-kilobase region on the short arm of chromosome 8.
Q42439709Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched.
Q92860654Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers
Q114182490Mendelian randomisation study of smoking exposure in relation to breast cancer risk
Q97528612Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival
Q33555064Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer
Q55387708Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer.
Q34497352MicroRNA related polymorphisms and breast cancer risk
Q34123806Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls
Q48221533Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology
Q37362211Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers
Q57305979Molecular Characterization and Cancer Risk Associated with BRCA1 and BRCA2 Splice Site Variants Identified in Multiple-Case Breast Cancer Families
Q57306007Molecular characterization and cancer risk associated withBRCA1 andBRCA2 splice site variants identified in multiple-case breast cancer families
Q53829480Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
Q34736858Most common 'sporadic' cancers have a significant germline genetic component
Q24310445Most germ-line mutations in the nevoid basal cell carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident
Q35802557MspI RFLP of FSHB on chromosome 11p
Q42514809Multidimensional phenotyping of breast cancer cell lines to guide preclinical research
Q36897003Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
Q25257392Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer
Q64386822Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families
Q44341959Mutation analysis of five candidate genes in familial breast cancer
Q40426350Mutation and expression analysis of LZTS1 in ovarian cancer
Q50613227Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.
Q49024646Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations.
Q42450636Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women
Q27860760Mutations of the BRAF gene in human cancer
Q24336457Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome
Q52675313MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.
Q24629025NcoI RFLP of the human LHRH gene on chromosome 8p
Q26799669Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk
Q40678901Nevoid basal cell carcinoma syndrome: review of 118 affected individuals
Q37356243Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2.
Q97430909Nicholas Gordon Martin
Q30275832No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival
Q37237352No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study
Q30374367No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Q54396803No evidence for an association between the earwax-associated polymorphism in ABCC11 and breast cancer risk in Caucasian women.
Q24800108No evidence for association of ataxia-telangiectasia mutated gene T2119C and C3161G amino acid substitution variants with risk of breast cancer
Q74736372No evidence for microsatellite instability from allelotype analysis of benign and low malignant potential ovarian neoplasms
Q42452827No evidence for the H133Y mutation in SONIC HEDGEHOG in a collection of common tumour types
Q51699099No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Q37308596No evidence that GATA3 rs570613 SNP modifies breast cancer risk
Q37079859No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing
Q24806182No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer
Q43589119No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer
Q92476025Non-coding RNAs underlie genetic predisposition to breast cancer
Q89927576Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D
Q47298863Ovarian cancer risk, ALDH2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association Consortium
Q38400931Ovarian cancer survival and polymorphisms in hormone and DNA repair pathway genes
Q36280191Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
Q28584533PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS
Q33586121Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer
Q40070779Panel sequencing of 264 candidate susceptibility genes and segregation analysis in a cohort of non-BRCA1, non-BRCA2 breast cancer families.
Q34289136Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche
Q112572520Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes
Q35737888Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
Q29547841Patterns of somatic mutation in human cancer genomes
Q35177861Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients
Q34522502Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant
Q62583133Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
Q97524107Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants
Q33891803Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium
Q24648412Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women
Q31835337Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype
Q36066735Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression
Q33921008Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium
Q33747831Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the ovarian cancer association consortium
Q34780052Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers
Q45062920Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry
Q96431220Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer
Q40216095Prediction of BRCA1 and BRCA2 mutation status using post-irradiation assays of lymphoblastoid cell lines is compromised by inter-cell-line phenotypic variability
Q36583004Prediction of breast cancer risk based on profiling with common genetic variants
Q55094933Primary treatment patterns in women recruited to the Australian Ovarian Cancer Study.
Q35223238Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort
Q57306049Progesterone receptor polymorphisms and risk of breast cancer: results from two Australian breast cancer studies
Q45187094Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.
Q36614790Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis
Q96027123Prognostic gene expression signature for high-grade serous ovarian cancer
Q57265866Prohibitin 3′ untranslated region polymorphism and breast cancer risk in Australian women
Q35223068Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer
Q35879159PstI RFLP of the CGB gene
Q55508030Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.
Q90242034Publisher Correction: Shared heritability and functional enrichment across six solid cancers
Q36512097RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies
Q36009422RAD51B in Familial Breast Cancer
Q57306054RAD52 Y415X truncation polymorphism and epithelial ovarian cancer risk in Australian women
Q33917622Rad51 supports triple negative breast cancer metastasis
Q114182625Rare germline copy number variants (CNVs) and breast cancer risk
Q73115092Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours
Q35608690Rare variants in the ATM gene and risk of breast cancer
Q37373918Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer
Q36615915Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma
Q28365024Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas
Q35155449Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia
Q48018693Regressive logistic and proportional hazards disease models for within-family analyses of measured genotypes, with application to a CYP17 polymorphism and breast cancer
Q57269231Reproductive hormone genes in mothers of spontaneous dizygotic twins: an association study
Q45951126Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study.
Q36467883Restriction fragment length polymorphisms of L-myc and myb in human leukaemia and lymphoma in relation to age-selected controls
Q37300024Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042.
Q37624504Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10
Q37453871Role of genetic polymorphisms and ovarian cancer susceptibility
Q37188838Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium
Q97883645SNPs in lncRNA Regions and Breast Cancer Risk
Q59270771Searching for BRCA3 by exome sequencing
Q63681731Sequence variants ofDLC1 in colorectal and ovarian tumours
Q36089391Shared genetics underlying epidemiological association between endometriosis and ovarian cancer
Q61118451Shared heritability and functional enrichment across six solid cancers
Q64004349Shared heritability and functional enrichment across six solid cancers
Q41499061Simple repeat polymorphism at the D9S151 locus.
Q37151786Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer
Q54254464Sodium butyrate differentially modulates plasminogen activator inhibitor type-1, urokinase plasminogen activator, and its receptor in a human colon carcinoma cell.
Q71254196Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer
Q70147998Somatic rearrangement of the c-myc oncogene in primary human diffuse large-cell lymphoma
Q44039296Spastic paresis, glaucoma and mental retardation--a probable autosomal recessive syndrome?
Q42463910Subtypes of familial breast tumours revealed by expression and copy number profiling
Q38955844Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors
Q33566957TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer
Q50690518Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer.
Q37025837Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families
Q57250694The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Q46594966The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case-control and family analysis
Q36921422The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin
Q43754304The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years.
Q49817640The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity.
Q33675997The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers
Q57265871The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer
Q42084911The EcoRI RFLP of c-mos in patients with non-Hodgkin's lymphoma and acute lymphoblastic leukemia, compared to geriatric and non-geriatric controls
Q91178389The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer
Q34115636The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers
Q52673733The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers.
Q46950536The MnSOD Val9Ala polymorphism, dietary antioxidant intake, risk and survival in ovarian cancer (Australia).
Q37578078The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers
Q35781316The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients
Q37401496The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
Q24797305The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers
Q34306268The application of nonsense-mediated mRNA decay inhibition to the identification of breast cancer susceptibility genes
Q59292171The challenges of finding the gene responsible for a rare, autosomal dominant gastric cancer susceptibility syndrome
Q42487051The diagnostic implication of falcine calcification on plain skull radiographs of patients with basal cell naevus syndrome and the incidence of falcine calcification in their relatives and two control groups
Q42457755The effects of splice site mutations in patients with naevoid basal cell carcinoma syndrome
Q34325260The human growth-arrest-specific gene GAS1 maps outside the candidate region of the gene for nevoid basal cell carcinoma syndrome
Q55445982The importance of using public data to validate reported associations.
Q24806016The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia
Q43545828The microsomal epoxide hydrolase Tyr113His polymorphism: association with risk of ovarian cancer.
Q39657980The molecular genetics of human non-Hodgkin's lymphoma
Q93063911The molecular origin and taxonomy of mucinous ovarian carcinoma
Q40455895The prevalence of cervical and thoracic congenital skeletal abnormalities in basal cell naevus syndrome; a review of cervical and chest radiographs in 80 patients with BCNS.
Q43993679The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women.
Q57306058The prohibitin 3′ untranslated region polymorphism is not associated with risk of ovarian cancer
Q35024008The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing
Q36142060The role of genetic breast cancer susceptibility variants as prognostic factors
Q38435382The role of glutathione-S-transferase polymorphisms in ovarian cancer survival
Q92832186The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries
Q42489919The spectrum of patched mutations in a collection of Australian basal cell carcinomas
Q43829398The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women.
Q55443510The use of the Illumina FFPE Restoration Protocol to obtain suitable quality DNA for SNP-based CGH– a pilot study.
Q47397232Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach
Q89961489Transcriptome-wide association study of breast cancer risk by estrogen-receptor status
Q38483754Transfer of chromosome 8 into two breast cancer cell lines: total exclusion of three regions indicates location of putative in vitro growth suppressor genes
Q46417337Translating Germline Cancer Risk into Precision Prevention
Q39169737Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor
Q57390853Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer
Q51974477Two ATM variants and breast cancer risk.
Q53488352UV induction of transforming growth factor alpha in melanoma cell lines is a posttranslational event.
Q47830753Urokinase receptor genotypes in colorectal cancer.
Q35602598Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib
Q37081074Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium
Q56342454Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility
Q33847791Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer
Q35012867Variation in the RAD51 gene and familial breast cancer
Q86450533WGS and targetted sequencing in acute lymphoblastic leukemia identifies putative enhancer mutation associated with over-expression of a growth factor
Q59078721What makes a good PhD student?
Q37144248What's in a cancer syndrome? Genes, phenotype and pathology
Q34177267Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk
Q98881532eQTL Colocalization Analyses Identify NTN4 as a Candidate Breast Cancer Risk Gene
Q44458999kConFab: a research resource of Australasian breast cancer families. Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer
Q37414133rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk
Q56334023rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology

Q75281807Nicholas Gordon MartinspouseP26

The articles in Wikimedia projects and languages

      Georgia Chenevix-Trenchwikipedia

Search more.